SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs steep slide to new lows is prompting debate over whether worsening sentiment around Trump and the approaching midterms is weighing on the stock, alongside skepticism about the companys limited underlying business. Most commenters are bearish and discuss shorting or further declines, while a smaller group sees the drop as a buying opportunity; no single confirmed company announcement dominates the conversation.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-guided third-quarter report and an upbeat 2027 earnings outlook are driving CLFs rally. Traders are optimistic about a steel-sector recovery and potential short covering, while others question whether the outlook can overcome debt concerns and sustain the move.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The FDAs early expansion of ANKTIVA plus BCG to papillary-only BCG-unresponsive bladder cancer has dominated discussion, but shares sold off sharply despite the approval and favorable trial updates. Traders debate a sell-the-news move and broader biotech weakness against concerns about commercial uptake, revenue, valuation and financing; claims of coordinated shorting remain speculation.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs upcoming Q3 earnings report is the main focus, with traders debating whether guidance and advertising momentum can offset concerns about slowing engagement and subscriber growth. The stocks weakness, analyst target cuts, layoffs, and a content-chief change fuel bearish sentiment, while some investors see low expectations as room for a rebound.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

CEO Scott Kirbys reported support for a 100% inheritance tax is drawing sharp criticism, with some traders calling for a boycott or selling UAL shares. Others are focused on upcoming earnings and fuel-cost risks, but the tax comments dominate the immediate discussion.

AGNC Investment Corp. engages in the operation of a real estate investment trust. The firm invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It also invests in other types of mortgage and mortgage-related securities, such as credit risk transfer securities and non-Agency residential and commercial mortgage-backed securities, where repayment of principal and interest is not guaranteed by the United States government-sponsored enterprise or by the United States Government agency, and other assets related to the housing, mortgage, or real estate markets. The company was founded on January 7, 2008 and is headquartered in Bethesda, MD.

AGNC Investment Corp

AGNCs third-quarter results drew attention after tangible book value fell sharply and recurring spread income only narrowly covered the dividend, intensifying concerns about the mortgage REITs valuation and payout sustainability. Traders are divided between selling amid rate and mortgage-spread pressures and buying the depressed shares for their high yield.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP is drawing attention amid a sharp rare-earth and critical-minerals sector selloff, with traders pointing to persistent lower lows, weak price action and macro pressure from yields and rates. Some see a possible bargain and cite U.S. supply-chain priorities and government backing, while others worry that China negotiations could ease supply concerns and keep the sector under pressure.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Ahead of its quarterly results, AAL is drawing attention over concerns that elevated oil and jet-fuel costs will squeeze margins, with traders also citing the airlines heavy debt and risk of weaker guidance. Bears expect continued pressure or an earnings warning, while some investors view the recent decline as a buying opportunity if fuel costs ease.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS CEO Angelos Stergious anniversary post and reference to a next chapter sparked speculation among traders about an imminent REGAL trial update or possible deal. Others called it a routine anniversary message and noted that no clinical news was confirmed; the main focus remains REGALs final analysis, triggered at 80 events after the last disclosed count of 78.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Morgan Stanleys upgrade of Amazon to a top pick, citing stronger AWS growth prospects tied to AI demand, is drawing attention alongside the sharp share gain. Traders are upbeat about AWS and AI, while some question whether the analyst call can sustain momentum and are watching for earnings and technical resistance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus to Participate in Chardans 10th Annual Healthcare Investor Conference

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardans 10th Annual Healthcare Conference: The Next 10 Years of...

Armenia Grants First Marketing Authorizations for Agenus BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo (botensilimab, BOT) and Evamplix (balstilimab, BAL), each approved for use in combination with the other for...

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus multifunctional, Fc-enhanced anti-CTLA-4 antibody, in...

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at...

Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday

U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.read more...

Agenus to Participate in Upcoming September Investor Conferences

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor...

Agenus Announces Peer-Reviewed Publication Linking BOT+BALs Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced antiCTLA-4 antibody, plus balstilimab (BAL), an antiPD-1...

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus multifunctional, Fc-enhanced anti-CTLA-4 antibody, and...

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus...

This account has been verified as an official AGEN representative.

Verified Account

Agenus Communications

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment

Equity

Extremely Bearish Sentiment

<ul class="summary-bullets"><li>Net proceeds from the financing are slated to fund a late-stage colon cancer clinical trial and potentially provide cash runway through 2031.</li><li>Agenus is also shifting its main drug combination to treat high-risk, earlier-stage colon cancer before surgery.&nbsp;</li><li>The condition represents a potential U.S. market opportunity of more than $7 billion annually, Agenus said.</li></ul><p><br>Agenus (AGEN) shares jumped 100% on Monday after the company announced an oversubscribed private placement of up to $340 million and a strategic pivot to prioritize its lead program in earlier-stage colon cancer.</p><p>The stock is now on track for its best day ever, if gains hold.</p><h2 class="st-heading-2">Financing Details</h2><p>Agenus is raising up to $340 million from investors through a private deal. It expects to receive about $85 million soon, with the potential for another $255 million later if investors buy more shares.</p><p>Net proceeds from the financing are slated to fund a late-stage colon cancer clinical trial and potentially provide cash runway through 2031.</p><p>The company had just $35.0 million in cash and cash equivalents as of March 31.</p><h2 class="st-heading-2">New Pipeline Focus</h2><p>Agenus is shifting its main drug combination (botensilimab plus balstilimab) to treat high-risk earlier-stage colon cancer before surgery, the company said. It now plans a large, late-stage study in the patient population, with the first patient expected to be dosed in the first quarter of 2027. The condition represents a potential U.S. market opportunity of more than $7 billion annually, Agenus said.</p><p>At the same time, Agenus is stopping financial support for a different study in patients with more advanced colon cancer. Earlier, smaller studies of the drug combination showed promising results, with many patients responding well to the treatment, it noted.</p><h2 class="st-heading-2">Expert Takeaway</h2><p>H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Agenus to $30 from $23 and kept a ‘Buy’ rating on the shares. H.C. Wainwright views the shift in strategy as favorable, saying there is currently no standard of care in neoadjuvant treatment for the condition. The firm’s new price target represents a potential upside of about 796% from the stock’s last closing price.</p><p>On X, the investor commonly referred to as ‘Pharma bro,’ Martin Shkreli wrote, “short $AGEN - PIPE does not change bleak outlook. should trade back to PIPE price.”</p><h2 class="st-heading-2">How Did AGEN Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AGEN stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.</p><p>A Stocktwits user expressed optimism for the pipeline pivot, increasing the market potential of the company’s drug combination.</p><p><stembedurl>https://www.stocktwits.com/jcilip/message/658917933</stembedurl></p><p>Another user voiced hopes for a further rally.</p><p><stembedurl>https://www.stocktwits.com/M105/message/658921495</stembedurl></p><p>According to data from Koyfin, both the analysts covering AGEN rate it a ‘Buy.’ The 12-month average price target on the stock is $15.50, representing a potential upside of 363% from the stock’s Friday close.</p><p><a href="https://stocktwits.com/symbol/AGEN">AGEN stock</a> has more than doubled year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kvue-stock-dips-after-court-revives-tylenol-autism-lawsuits/cZmzDliR7Yj">KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Agenus logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Agenus expects to receive about $85 million soon under a placement, with the potential for another $255 million later. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.28	--	--	N/A
Q2 '26	$0.05	--	--	N/A
Q1 '26	$2.10	--	--	N/A
Q4 '25	-$1.04	--	--	N/A
Q3 '25	$2.20	$1.94	-11.68%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

AGEN Earnings

Upcoming Earnings: Q3 '26

Historical Earnings